This study was done to improve efficiency and islet specificity of the rat insulin promoter (RIP). Various RIP lengths were prepared and tested in vitro to drive luciferase reporter gene expression in INS1-cells, a-cells, acinar cells, ductal cells and fibroblasts. The CMV promoter was used as a positive control. In addition, the DsRed reporter gene was administered in vivo to rat pancreas by ultrasound-targeted microbubble destruction (UTMD). Confocal microscopy was used to detect the presence and distribution of DsRed within the pancreas after UTMD. A modified RIP3.1 promoter, which includes portions of the insulin gene after its transcription start site is fivefold more active in INS-1 cells than the full-length RIP promoter or the CMV promoter. RIP3.1 is regulated by glucose level and various islet transcription factors in vitro, and exhibits activity in a-cells, but not in exocrine cells. In vivo delivery of RIP3.1-DsRed resulted in expression of DsRed protein in b-cells, and to a lesser extent in a-cells under normal glucose conditions. No DsRed signal was present in exocrine pancreas under RIP3.1. A modified RIP, RIP3.1, efficiently and specifically directs gene expression to endocrine pancreas.
Introduction
Novel therapeutic strategies, including islet transplantation and gene therapy, are being sought to treat diabetes, which is increasing in prevalence worldwide. [1] [2] [3] Gene therapy requires direct targeting of genes to the islets in vivo. So far, adenovirus, adeno-associated virus, lentivirus and herpes simplex virus-1 vectors have enabled efficient gene transfer to islets, but suffer from host immune responses and vector cytotoxicity. [4] [5] [6] [7] [8] [9] [10] Non-viral gene delivery systems, including naked DNA and DNA complexes, induce islet cell transfection at much lower levels and with only transient transgene expression. However, non-viral vector systems will more easily satisfy biosafety concerns in clinical trials.
We have recently shown that ultrasound-targeted microbubble destruction (UTMD) is able to target gene delivery to pancreatic islets in vivo. 11, 12 Gas-filled microbubbles, containing plasmids, are injected intravenously and destroyed within the pancreatic microcirculation by ultrasound, thereby delivering the plasmids through the vascular endothelial barrier. This approach enables transfection of the islet core, wherein most b-cells reside.
We have previously shown that combining UTMD with a rat insulin promoter (RIP) enhances b-cell specificity. 11 We now show differential efficiency of transgene expression by varying the length of the RIP promoter sequence. We attempted to expand insulin gene promoter to include non-coding regions in exon1, intron1 and part of exon2 of the rat insulin gene 1, driving a downstream reporter gene. We report that a modified RIP promoter (RIP3.1) enables b-cell-specific glucoseregulatable gene expression in cell culture. In addition, in vivo delivery of reporter genes under control of RIP3.1 by UTMD provides islet-specific, efficient and regulated transgene expression in rats. Figure 1 illustrates the dual luciferase ratio for the various RIP promoter lengths under with or without glucose after transfection on rat INS-1 cell line. Under glucose condition, the luciferase ratio of RIP3.1-luc is 7000-fold greater than RIP2.1-luc (truncated RIP promoter), fivefold greater than RIP1.1-luc (full-length RIP) and fivefold greater than CMV-luc (Po0.001). Under absent glucose condition, the luciferase ratio is significantly blunted in all groups, but remains higher with RIP3.1 than with other RIP lengths and CMV (Po0.001). For each different promoter, the ratio of glucose/no glucose luciferase activity was of the same order of magnitude, ranging from 8-to 15-fold. Surprisingly, luciferase activity could be detected from the culture media solution of RIP3.1 dish at 8, 16, 24, 32 and 48 h after transfection under with glucose conditions (Figure 1b ). No excretion of luciferase into culture media was seen under absent glucose (data not shown). Figure 2 shows the results of RIP3.1-driven luciferase versus CMV-driven luciferase activity in various cell lines. The luciferase ratio is similar in all pancreatic cell lines when luciferase is under control of the CMV promoter. However, the RIP3.1 promoter results in a luciferase ratio that is fourfold higher than CMV in INS-1 cells. Likewise, RIP3.1 results in 4-fold higher luciferase ratio in INS-1 cells than in a cells and 35-fold greater luciferase ratio compared with pancreatic exocrine cell lines (acinar, duct and fibroblast cell lines) (Po0.001). RIP3.1 and CMV promoters exhibit similar activity in a-cells, but is nearly absent in exocrine cell lines compared with CMV. Figure 3 illustrates dual luciferase ratio for the various RIP promoter lengths under with or without glucose after transfection on mouse a TC1 clone9 cell line. Under glucose condition, the luciferase ratio of RIP3.1-luc is 400fold greater than RIP2.1-luc (truncated RIP promoter), and 3-fold greater than RIP1.1-luc (full-length RIP) (Po0.001). However, under absent glucose condition, the luciferase ratios are about 0.5-fold higher than under glucose condition (Po0.001). RIP3.1-luc and CMV-luc show nearly identical luciferase ratios regardless of glucose conditions. Regulation of the RIP3.1 promoter by islet transcription factor genes Figure 4 shows the regulation of the RIP3.1 promoter by various islet transcription factors. RIP3.1-NeuroD1 and RIP3.1-Mafa significantly upregulate the RIP3.1mediated luciferase activity (Po0.001), whereas the Nkx6.1, Nkx2.2 and PAX4 downregulate it (Po0.001). PDX-1 and Ngn3 result in a minimal but statistically significant upregulation of RIP3.1-mediated luciferase activity (P ¼ 0.010274). Nearly identical results were obtained when the CMV was used to drive islet transcription factors, confirming that NeuroD1 and MafA significantly upregulate the RIP3.1 promoter, whereas 
Results

RIP-luc transfection on pancreatic cell lines
RIP3.1-DsRed plasmids delivered to pancreatic islets in vivo with UTMD
To better understand gene expression and regulation of these RIP promoters in islets of living animals, we further delivered these RIP-DsRed plasmids in vivo using UTMD. Rats were killed 4 days after UTMD. Figure 5 shows that DsRed protein under the regulation of RIP3.1 (panel a) and RIP4.1 (panel b) was detected in intact islets, but not in exocrine pancreas. Confocal images showed that DsRed protein was detected in both b-cells and, to a lesser extent, in a-cells. DsRed protein signal was much lower with full-length RIP1.1 (panel c) and nearly absent with truncated RIP2.1 (panel d). DsRed protein was seen in both the endocrine and exocrine pancreas in rats treated with CMV-DsRed plasmid (panel e). There was no detectable DsRed protein in the pancreas of normal control rats (panel f).
Next, we wanted to know whether gene expression of delivered RIP plasmids was regulated by glucose as in the INS-1 cell line. We used RIP3.1-DsRed because of its higher efficiency, and treated two groups of rats, fasting (12 h) and feeding with 10% of glucose. Figure 6 (top panel) shows DsRed signal in both b-cells and, to a lesser extent, in a-cells of islets in rats fed on 10% glucose. In contrast, fasting rats only exhibited DsRed signal in a-cells. This suggests that glucose feeding induced upregulation of RIP3.1-DsRed gene expression in whole islets cells and that fasting (low glucose level) downregulated RIP3.1-DsRed gene expression in b-cells but not in a-cells.
Discussion
Most of the previous studies of the insulin promoter have been performed using the sequence before the transcriptional start site, usually ending after the TATA box. [13] [14] [15] [16] [17] The RIP3.1 insulin promoter includes non-coding regions Transgene expression by a modified rat insulin promoter R Chai et al after the transcription start site, including exon I, intron I and part of exon II. Our study is the first report that the promoter RIP3.1 is much more efficient than the traditional insulin gene promoter, or the widely used CMV promoter. Thus, the non-coding exon and intron regions seem to be essential to generate robust b-cell (and to a lesser extent, a-cell) specific transgene expression. Moreover, RIP3.1 showed secretion of the encoded protein under high glucose conditions in cell culture. Studies of the insulin promoter have revealed that the regulation of insulin gene is restricted to the pancreatic islets cells and regulated by glucose. [18] [19] [20] [21] The RIP3.1 promoter exhibited cell-specific gene expression in islets cell lines when compared with that in exocrine pancreatic cell lines; the luciferase activity of RIP3.1 plasmid in b
cell is 4-fold greater than in a cell, 35-fold greater than in pancreatic duct cell and 300-fold greater than in pancreatic acinar cells. The lower levels of gene expression of RIP3.1 in a-cell lines are likely explained by homologous DNA sequence motifs like E1 or A boxes in regulation areas of the glucagon and insulin genes. 22, 23 In addition, RIP3.1 promoter showed glucose responsiveness in both b-cells and a-cells. In b-cells, the promoter activity under with glucose condition (1 g l À1 ) is 10-fold greater than under absent glucose condition. It has already been shown that the promoter elements upstream of À230 are involved in the glucose-mediated suppression of the insulin promoter activity. 24 In a-cells, the promoter activity under absent glucose conditions is 1.5-fold greater than under glucose condition. This might Our study is the first to report the activity of seven islets transcription factors (PDX-1, Ngn3, NeuroD1, Pax4, Nkx2.2, Nkx6.1 and Mafa) in regulating the insulin promoter in INS-1 cells. [25] [26] [27] [28] [29] [30] [31] When RIP3.1-luc plasmids were cotransfected with these transcription factor genes under the CMV promoter, NeuroD1 and Mafa increased luciferase activity by 104 and 44%, respectively. Pdx-1 and Ngn3 increased luciferase activity only slightly, whereas Pax4, Nkx2.2 and Nkx6.1 significantly decreased it. When RIP3.1-luc was cotransfected with these transcription factors under the RIP3.1 promoter, the same effects were seen, confirming that NeuroD1 and Mafa upregulate the RIP3.1 promoter, whereas Pax4, Nkx2.2 and Nkx6.1 downregulate it. We designed a RIP3.1-neo control plasmid that could rule out the likely interference effects by the endogenous transcription factors when cotransfected in INS-1. Further studies are needed to elucidate the mechanism(s) by which this occurs. However, it is likely that the effects of these transcription factors on the RIP3.1 promoter are explained by the presence of additional binding sites. For example, the insulin gene has four cAMP response elements (CRE), CRE1 at À210; CRE2 at À183; CRE3 at +18 and CRE4 at +61. 32 The RIP3.1 promoter contains two more of these CRE boxes than the standard RIP1.1 promoter. In addition, RIP3.1 contains additional cis-elements such as Nir-box, 33 GAGA-box, 34 Pl-box 35 and an AGGAT motif at +87 and +110 for the binding of the ets-family of transcription factors. 36 To confirm that the results of the in vitro experiments were physiologically relevant, we used UTMD to deliver the RIPs-dsRed plasmids to the pancreas of the living animal in vivo. Immunohistological staining showed that the RIP3.1 promoter is more effective than other promoter lengths for driving transgene expression in pancreatic islets. DsRed signal was only seen in the intact islets and not in the exocrine pancreas. This high transgene expression by RIP3.1 might be related to two more CRE boxes and a C box in exon1 and intron1, which are not present in the truncated (RIP2.1) or the normal (RIP1.1) insulin promoters. We also found that RIP3.1 activity was regulated by glucose. This is the first report that we can manipulate transgene expression of pancreatic islets at the transcriptional level in living animals by fasting or feeding, which is not a feature of virus-mediated gene therapy. Careful attention to promoter biology may help target gene therapy for diabetes to the islets, and allow feedback regulation of the transgene in a physiological manner.
Materials and methods
RIPs and plasmids constructs
Rat genomic DNA was extracted from Sprague-Dawley rat peripheral blood with a QIAamp Blood kit (Qiagen Inc., Valencia, CA, USA). Four different length rat insulin I gene promoters, named RIP2.1 (À412 to À303); RIP1.1 (À412 to À1); RIP4.1 (À412 to +43) and RIP3.1 (À412 to +165), were designed (Figure 7) . The rat insulin I gene promoters were PCR amplified from rat genomic DNA by using forward and reverse primers containing either KpnI-HindIII or xhoI-EcoRI restriction site, respectively. The sequences of these primers are listed in Table 1 . The corresponding PCR products were verified by agarose gel electrophoresis and purified by QIAquick Gel Extraction kit (Qiagen Inc.). To confirm the sequences, direct sequencing of PCR products was performed with dRhodamine Terminator Cycle Sequencing Kit (PE Applied Biosystems, Foster, CA, USA) on an ABI 3100 Genomic Analyzer (Applied Biosystems, Foster, CA, USA). Then PCR products were subcloned into the pGL3-basic firefly luciferase reporter plasmid (Promega, Madison, WI, USA) and pDsRed1-1 reporter vector (Clonetech, Mountain View, CA, USA). hMafa cDNA and hamster NKX6.1 cDNA were generously donated by the Olson laboratory at Michigan State University and the Newgard laboratory at Duke University Medical Center, respectively. Rat Ngn3, NeuroD1, PAX4 and Nkx2.2 cDNAs were PCR products from Sprague-Dawley newborn rat pancreas cDNA pool that were reversed from their total RNA according to the manufacturer's instructions. The sequences of these primers are listed in Table 1 . Newborn rat pancreatic samples were flash frozen in liquid nitrogen and stored at À86 1C. The frozen samples were thawed in 1 ml of RNA-STAT solution and immediately homogenized using a polytron 3000 homogenizer (Brinkman Instruments, Mississauga, Canada) at 10 000 r.p.m. for 30 s. Total RNA (30 ng) was reverse transcribed into 20 ml cDNA solution by using a Sensiscript RT Kit (Qiagen Inc.) with oligo(dT)16. The Transgene expression by a modified rat insulin promoter R Chai et al reaction mixture was incubated at 42 1C for 50 min, followed by a further incubation at 70 1C for 15 min. PCR was performed for all samples using a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA) in 50 ml volume containing 2 ml cDNA, 25 ml of HotStarTaq Master Mix (Qiagen Inc.) and 20 pmol of each primer ( Table 1) . The corresponding PCR products were verified by agarose gel electrophoresis and purified by QIAquick Gel Extraction kit (Qiagen Inc.). To confirm the sequences, direct sequencing of PCR products was performed with dRhodamine Terminator Cycle Sequencing Kit on an ABI 3100 Genomic Analyzer. All transcriptional factor gene cDNAs were subcloned to RIP3.1 driving vector and pCI vector (Promega). The plasmid digestion, ligation, subclone, isolation and purification were performed by standard procedures, and once again sequenced to confirm that no artifactual mutations were present. 
Cell culture and transient transfection assays
Rat UTMD protocol
Sprague-Dawley rats (250-350 g) were anesthetized with intraperitoneal ketamine (100 mg kg À1 ) and xylazine (5 mg kg À1 ). A polyethylene tube (PE 50, Becton Dickinson, San Jose, CA, USA) was inserted into the right internal jugular vein by cutdown. The anterior abdomen was shaved and an S3 probe (Sonos 5500, Philips Ultrasound, Andover, MA, USA) was placed to image the left kidney and spleen, which are easily identified. The pancreas lies between them; therefore the probe was adjusted to target the pancreas and clamped in place. In total, 1 ml of microbubble solution was infused at a constant rate of 3 ml h À1 for 20 min using an infusion pump. Throughout the duration of the infusion, microbubble destruction was achieved using ultraharmonic mode (transmit 1.3 MHz/receive 3.6 MHz) with a mechanical index of 1.2-1.4 and a depth of 4 cm. The ultrasound pulses were Electrocardiography triggered (at 80 ms after the peak of the R wave) to deliver a burst of four ultrasound pulses every four cardiac cycles. At the end of each experiment the jugular vein was tied off and the skin was closed. All the rats were monitored after the experiment for normal behavior. Rats were killed 4 days later and the pancreas was harvested.
Manufacture of plasmid-containing lipid-stabilized microbubbles
Lipid-stabilized microbubbles were prepared as previously described in our laboratory. 11, 12 Briefly, a solution of DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, Sigma, St Louis, MO, USA) 2.5 mg ml À1 ; DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, Sigma) 0.5 mg ml À1 and 10% glycerol was mixed with 2 mg of plasmid solution in a 2:1 ratio. Aliquots of 0.5 ml of this phospholipid-plasmid solution were placed in 1.5 ml clear vials; the remaining headspace was filled with perfluoropropane gas (Air Products Inc., Allentown, PA, USA). Each vial was incubated at 40 1C for 30 min and then mechanically shaken for 20 s by a dental amalgamator (VialmixTM, Bristol-Myers Squibb Medical Imaging, N. Billerica, MA, USA). The lipid-stabilized microbubbles appear as a milky white suspension floating on the top of a layer of liquid containing unattached plasmid DNA. The subnatant was discarded and the microbubbles were washed thrice with phosphate buffer solution (PBS) to remove unattached plasmid DNA. Mean diameter and concentration of the microbubbles were measured by a particle counter (Coulter Multisizer III, Beckman, Miami, FL, USA). 
Immunohistochemistry for detection of DsRed protein, insulin and glucagon
Cryostat sections 5-8 mm in thickness were fixed in 4% paraformaldehyde for 15 min at 4 1C and quenched for 5 min with 10 mM glycine in PBS. Sections were then rinsed in PBS thrice, and permeabilized with 0.5% Triton X-100 in PBS for 10 min. Sections were blocked with 10% goat serum at 37 1C for 1 h and washed with PBS thrice. The primary antibodies, mouse anti-insulin (Sigma, 1:10 000 dilution), rabbit anti-glucagon (Chemicon, Temecula, CA, USA, 1: 500 dilution), rabbit anti-DsRed (1:500 dilution), were added and incubated at RT for 2 h. After washing with PBS thrice for 5 min, the secondary antibody (anti-mouse lgG conjugated with FITC) (1:500 dilution in block solution) and anti-rabbit IgG-Cy5 (1:250 dilution) were added and incubated for 1 h at RT. Sections were rinsed with PBS for 10 min, five times, and then mounted.
Statistical analysis
Differences in luciferase activity between experimental groups were compared by two-way ANOVA. A P-value o0.001 was considered statistically significant. Post-hoc Scheffe tests were performed only when the ANOVA F-values were statistically significant.
